Morgan Stanley

A chessboard with blocks that read MA

Pharma

As patent cliffs loom, Morgan Stanley predicts pharma M&A surge

Patent cliffs are looming, but many biopharma companies have enormous capacity to respond, according to a recent research note from Morgan Stanley.

Kevin Dunleavy Jul 15, 2024 11:42am

Eli Lilly

Lilly, AbbVie set for success late in decade, but BMS may suffer

Apr 7, 2022 3:15pm

TV with color bands

Big Pharma leads the charge in TV ad spending increases, analyst report finds

Jun 1, 2016 8:01am